Page last updated: 2024-11-01
ofloxacin and Besnier-Boeck Disease
ofloxacin has been researched along with Besnier-Boeck Disease in 1 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "Sarcoidosis is a chronic granulomatous disease for which there are limited therapeutic options." | 2.78 | Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study. ( Aboud, C; Algood, H; Boyd, AS; Braun, N; Burke, VE; Drake, WP; Isom, J; Kaminski, N; King, LE; Oswald-Richter, K; Pandit, KV; Richmond, BW; Taylor, T; Yu, C, 2013) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Drake, WP | 1 |
| Oswald-Richter, K | 1 |
| Richmond, BW | 1 |
| Isom, J | 1 |
| Burke, VE | 1 |
| Algood, H | 1 |
| Braun, N | 1 |
| Taylor, T | 1 |
| Pandit, KV | 1 |
| Aboud, C | 1 |
| Yu, C | 1 |
| Kaminski, N | 1 |
| Boyd, AS | 1 |
| King, LE | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| Phase I/II Study of the Effects of Antibiotics on Sarcoidosis Pathogenesis[NCT01074554] | Phase 1/Phase 2 | 30 participants (Actual) | Interventional | 2010-02-28 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Change in Lesion Size at the Completion of Antibiotic Therapy, Measured on a Continuous Scale; Change Will be Determined by Change in Diameter of the Lesions
(NCT01074554)
Timeframe: Baseline to 8 weeks
| Intervention | mm (Median) |
|---|
| Antibiotic Regimen | -8.4 |
| Placebo Regimen | 0.07 |
Change in Modified Sarcoidosis Activity and Severity Index (SASI) at Completion of Therapy.
Characterization of lesion severity was conducted using Modified Sarcoidosis Activity and Severity Index (SASI), measuring erythema, induration and desquamation. The modification was that the same scale was applied to any part of the body, instead of the face alone. The scale range is 0 (no problem) to 72 (very severe). (NCT01074554)
Timeframe: Baseline to 8 weeks
| Intervention | units on a scale (Mean) |
|---|
| Antibiotic Regimen | -2.9 |
| Placebo Regimen | -0.6 |
Granuloma Burden
Number of patients with a decrease in Granuloma Burden (only in those patients having granulomas present at baseline biopsy) (NCT01074554)
Timeframe: Baseline to 8 weeks
| Intervention | participants (Number) |
|---|
| Antibiotic Regimen | 7 |
| Placebo Regimen | 0 |
Trials
1 trial available for ofloxacin and Besnier-Boeck Disease